Insight Molecular Diagnostics (IMDX) Non-Current Debt (2017 - 2021)

Insight Molecular Diagnostics (IMDX) has 5 years of Non-Current Debt data on file, last reported at $178000.0 in Q3 2021.

• Quarterly Non-Current Debt fell 91.38% year-over-year to $178000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $178000.0 (down 91.38% YoY) and the FY2020 annual result came in at $1.5 million, down 20.84% from the prior year.
• Non-Current Debt slipped to $178000.0 in Q3 2021 per IMDX's latest filing, from $541000.0 in the prior quarter.
• The five-year high for Non-Current Debt was $2.6 million in Q2 2020, with the low at $159000.0 in Q1 2019.
• Average Non-Current Debt over 5 years is $1.1 million, with a median of $1.1 million recorded in 2017.
• Year-over-year, Non-Current Debt jumped 884.28% in 2020 and tumbled 91.38% in 2021.
• Insight Molecular Diagnostics' Non-Current Debt stood at $1.1 million in 2017, then sank by 67.57% to $347000.0 in 2018, then soared by 448.99% to $1.9 million in 2019, then slipped by 20.84% to $1.5 million in 2020, then sank by 88.2% to $178000.0 in 2021.
• Business Quant data shows IMDX's Non-Current Debt at $178000.0 in Q3 2021, $541000.0 in Q2 2021, and $951000.0 in Q1 2021.